GSK withdraws Tykerb application from the FDA

Thursday 12 July 2012

GlaxoSmithKline Plc announced that it has withdrawn an application from the US Food and Drug Administration for a new indication for its marketed cancer drug, Tykerb (lapatinib), a kinase inhibitor.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom